Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study

NCT06753981 · clinicaltrials.gov ↗

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Arterial Pulmonary Hypertension (PAH)

Interventions

DRUG: Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs

Sponsor

Qianfoshan Hospital

Collaborators

[object Object]
[object Object]